Gerhard Mueller
Plus aucun poste en cours
Profil
Gerhard Mueller served as Chairman at Polyneuron Pharmaceuticals AG, Director-Research at Axxima Pharmaceuticals AG, and Portfolio Manager at M.M.
Warburg & Co. KGaA.
He holds a doctorate degree from Technische Universität München.
Anciens postes connus de Gerhard Mueller
| Sociétés | Poste | Fin |
|---|---|---|
Axxima Pharmaceuticals AG
 Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Axxima Pharmaceuticals AG provided drug discovery and development services. It was a drug discovery company in the field of kinase inhibition. It specialized in kinase-based drug discovery aimed at treating certain forms of cancer. It had also focussed on on HIV, Hepatitis C, tuberculosis and one particular herpes virus infections. The company was headquartered in Munich, Germany. | Directeur Technique/Scientifique/R&D | 14/03/2005 |
Polyneuron Pharmaceuticals AG
 Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Président | - |
M.M. Warburg & Co. KGaA
 M.M. Warburg & Co. KGaA Investment ManagersFinance M.M. Warburg & Co. KGaA (MM Warburg & Co. PB) is the investment advisory subsidiary of M.M. Warburg & Co. Gruppe KGaA in Germany. Established in 1798, M.M.Warburg & Co. is one of the largest private banks in Germany. All their capital is held by private individuals, while the Bank is managed by its co-owners. Located in Hamburg, Frankfurt and Cologne with subsidiary private banks in Berlin, Braunschweig, Bremen, Hanover, Luxembourg and Zurich, Switzerland, MM Warburg & Co. PB is a universal bank which offers a comprehensive range of services and products including financial planning, asset management, securities advice, advice on alternative investments and advice on inheritance planning and foundations. | Gestionnaire de Portefeuille-Actions | - |
Formation de Gerhard Mueller
| Technische Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
M.M. Warburg & Co. KGaA
M.M. Warburg & Co. KGaA Investment ManagersFinance M.M. Warburg & Co. KGaA (MM Warburg & Co. PB) is the investment advisory subsidiary of M.M. Warburg & Co. Gruppe KGaA in Germany. Established in 1798, M.M.Warburg & Co. is one of the largest private banks in Germany. All their capital is held by private individuals, while the Bank is managed by its co-owners. Located in Hamburg, Frankfurt and Cologne with subsidiary private banks in Berlin, Braunschweig, Bremen, Hanover, Luxembourg and Zurich, Switzerland, MM Warburg & Co. PB is a universal bank which offers a comprehensive range of services and products including financial planning, asset management, securities advice, advice on alternative investments and advice on inheritance planning and foundations. | Finance |
Axxima Pharmaceuticals AG
Axxima Pharmaceuticals AG Miscellaneous Commercial ServicesCommercial Services Axxima Pharmaceuticals AG provided drug discovery and development services. It was a drug discovery company in the field of kinase inhibition. It specialized in kinase-based drug discovery aimed at treating certain forms of cancer. It had also focussed on on HIV, Hepatitis C, tuberculosis and one particular herpes virus infections. The company was headquartered in Munich, Germany. | Commercial Services |
Polyneuron Pharmaceuticals AG
Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | Health Technology |
